Merryman, Reid W. http://orcid.org/0000-0002-6360-3234
Castagna, Luca
Giordano, Laura
Ho, Vincent T.
Corradini, Paolo
Guidetti, Anna
Casadei, Beatrice
Bond, David A. http://orcid.org/0000-0003-0773-1829
Jaglowski, Samantha http://orcid.org/0000-0002-4335-2554
Spinner, Michael A.
Arai, Sally
Lowsky, Robert
Shah, Gunjan L. http://orcid.org/0000-0002-9977-0456
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
De Colella, Jean Marc Schiano http://orcid.org/0000-0001-9923-4808
Blaise, Didier http://orcid.org/0000-0002-5684-9447
Herrera, Alex F.
Shouse, Geoffrey http://orcid.org/0000-0002-7917-5713
Spilleboudt, Chloe
Ansell, Stephen M. http://orcid.org/0000-0003-1244-6758
Nieto, Yago
Badar, Talha
Hamadani, Mehdi http://orcid.org/0000-0001-5372-510X
Feldman, Tatyana A.
Dahncke, Lori
Singh, Anurag K.
McGuirk, Joseph P. http://orcid.org/0000-0002-0539-4796
Nishihori, Taiga http://orcid.org/0000-0002-2621-7924
Chavez, Julio
Serritella, Anthony V.
Kline, Justin
Mohty, Mohamad
Dulery, Remy http://orcid.org/0000-0002-5024-1713
Stamatoulas, Aspasia
Houot, Roch
Manson, Guillaume
Moles-Moreau, Marie-Pierre
Orvain, Corentin
Bouabdallah, Kamal
Modi, Dipenkumar http://orcid.org/0000-0001-6525-8844
Ramchandren, Radhakrishnan
Lekakis, Lazaros
Beitinjaneh, Amer
Frigault, Matthew J.
Chen, Yi-Bin http://orcid.org/0000-0002-9554-1058
Lynch, Ryan C.
Smith, Stephen D.
Rao, Uttam
Byrne, Michael
Romancik, Jason T.
Cohen, Jonathon B.
Nathan, Sunita http://orcid.org/0000-0001-7920-4265
Phillips, Tycel
Joyce, Robin M.
Rahimian, Maryam
Bashey, Asad
Ballard, Hatcher J.
Svoboda, Jakub
Torri, Valter
Sollini, Martina
De Philippis, Chiara
Magagnoli, Massimo
Santoro, Armando
Armand, Philippe http://orcid.org/0000-0001-6098-1603
Zinzani, Pier Luigi http://orcid.org/0000-0002-2112-2651
Carlo-Stella, Carmelo http://orcid.org/0000-0003-3144-0124
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01 CA23766, P30 CA008748)
U.S. Department of Health & Human Services | National Institutes of Health
Associazione Italiana per la Ricerca sul Cancro (20575)
Article History
Received: 18 November 2020
Revised: 19 January 2021
Accepted: 8 February 2021
First Online: 3 March 2021
Compliance with ethical standards
:
: RWM, LC, LG, VTH, PC, AG, BC, MAS, SA, RL, JMSdC, DB, LD, AKS, TB, GS, CS, SMA, AVS, M-PM-M, CO, KB, LL, A Beitinjaneh, UR, MM, RD, SN, TP, RMJ, MR, A Bashey, HJB, JTR, VT, MS, CdP, and MM—none. DAB—Honoraria: Seattle Genetics. SJ—Honoraria: Novartis, Kite, Juno, Takeda, CRISPR Therapeutics. GLS—Research funding: Janssen, Amgen. M-AP—honoraria from Abbvie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Kite/Gilead, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda. He serves on DSMBs for Cidara Therapeutics, Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. He has received research support for clinical trials from Incyte, Kite/Gilead, and Miltenyi Biotec. He serves in a volunteer capacity as a member of the Board of Directors of Be The Match (National Marrow Donor Program, NMDP), as well as on the CIBMTR Cellular Immunotherapy Data Resource (CIDR) Executive Committee. AFH—Research funding: BMS, Merck, Genentech, Inc./F. Hoffmann-La Roche Ltd., Gilead Sciences, Seattle Genetics, Immune Design, AstraZeneca, Pharmacyclics. Consultancy: BMS, Merck, Genentech, Inc./F. Hoffmann-La Roche Ltd., Gilead Sciences, Seattle Genetics, Karyopharm. Travel, Accommodation, Expenses: BMS. YN—Consultant: Affimed. Research funds: Astra Zeneca, Affimed, Novartis, Secura Bio. MH—Research Support/Funding: Takeda Pharmaceutical Company; Astellas Pharma. Consultancy: Incyte Corporation; ADC Therapeutics; Celgene Corporation; Pharmacyclics, Magenta Therapeutics, Omeros, AbGenomics, Verastem, TeneoBio. Speaker’s Bureau: Sanofi Genzyme, AstraZeneca. TAF—Consultant./Ad Board: Seattle Genetics/BMS/Celgene/Karyopharm/KITE. Honoraria: Takeda/Celgene/Seattle Genetics/AbbVie/Pharmacyclics/Janssen/KITE/BMS. Speaker Bureau: Takeda/Celgene/Seattle Genetics/AbbVie/Pharmacyclics/Janssen/KITE/BMS. JPM—Research funding from Novartis, Fresenius Biotech, Astellas, Bellicum Pharmaceuticals, Gamida Cell, Kite Pharmaceuticals, Pluristem Ltd., Juno Therapeutics, and AlloVir. Advisory board and travel accommodations/expenses from Kite Pharmaceuticals, Juno Therapeutics AlloVir. Honoraria from Kite Pharmaceuticals and AlloVir. TN—Research funding: Novartis and Karypharm. JC—Personal fees: Kite/Gilead, Novartis, Morphosys, Bayer, Epyzime, AstraZeneca, Genentech, Karyopharm, Celgene/Juno. Research Support: Merck. JK—Research funding: Merck. AS—Honoraria: Celgene. Consultancy: Takeda. Other: Pfizer. RH—Honoraria: BMS, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. GM—Honoraria: Bristol Myers Squibb. DM—Editorial board: MorphoSys. RR—Research funding: Merck. Consultancy/Advisory: BMS. MJF—Consultancy/Advisory board: Novartis, Kite/Gilead, Celgene/BMS, and Arcellx. Y-BC—Consulting: Magenta, Incyte, Abbvie, Daiichi, Equilium, Actinium, Takeda. RCL—Research funding: Juno Therapeutics, Takeda, TG Therapeutics, Incyte, Rhizen Pharmaceuticals, Bayer, Cyteir, Genentech. Consultancy: MorphoSys. SDS—Research funding: Acerta Pharma BV, Astrazeneca, Bayer, Beigene, Ayala, Bristol Myers Squibb, De Novo Biopharma, Genentech, Ignyta, Incyte Corporation, Merck, Sharp and Dohme Corp., Pharmacyclics, Portola Pharmaceuticals, Seattle Genetics. Consultancy or Advisory Board: Astrazeneca, Millenium/Takeda, Beigene, Karyopharm, KITE pharma. MTB—Research funding: Karyopahrm. Consulting: Concert, Celgene/Celularity. JBC—Research funding: BMS/Celgene. JS—Consultancy: Adaptive, AstraZeneca, Atara, BMS, Genmab, Imbrium, Pharmacyclics, and Seattle Genetics. Research Funding: AstraZeneca, BMS, Incyte, Merck, Pharmacyclics, Seattle Genetics, and TG. AS—Advisory Board: BMS, Servier, Gilead, Pfizer, Eisai, Bayer, MSD. Consultancy: Arqule, Sanofi. Speaker’s Bureau: Takeda, BMS, Roche, Abbvie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, Arqule, Lilly, Sandoz, Eisai, Novartis, Bayer, MSD. PA—Consultancy: Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome. Research funding (inst): Merck, BMS, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech, IGM, Kite. Honoraria: Merck, BMS. PLZ—Consultancy: Verastem, MSD, Eusapharma, Sanofi. Speaker’s Bureau: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, Immune Design, Celgene, Portola, Roche, Eusapharma, Kyowa Kirin. Advisory Board: Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, Immune Design, Celgene, Portola, Roche, Eusapharma, Kyowa Kirin, Sanofi. CC-S—Consultancy: Servier, ADC Therapeutics, Roche, Sanofi, BMS, Merck, Karyopharm. Honoraria: Janssen Oncology AstraZeneca. Research support: ADC Therapeutics, Rhizen Pharmaceuticals.